drugset / Trial / NCT04452565
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
RandomizedParallel-groupTriple-blindPrevention
Summary
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.
Timeline
- Start
- 2022-06-15
- Primary completion
- 2023-12-15
- Completion
- 2023-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | 200 mg | Oral |
| Comparator | CYCLO(PROLYLGLYCYL) | Small molecule | 30 mg | Oral |
| Subject | Dexamethasone | Small molecule | 4 mg | Oral |